Brii Biosciences Limited (2137.HK) released end-of-treatment data from its Phase 2b ENRICH and ENHANCE studies evaluating combination regimens for chronic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE